AKRO Logo

Akero Therapeutics, Inc. (AKRO) 

NASDAQ$44.15
Market Cap
$3.52B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
46 of 924
Rank in Industry
35 of 527

AKRO Insider Trading Activity

AKRO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$9,600,00011
Sells
$39,672,2797299

Related Transactions

Graham G. Walmsleydirector1$9.6M0$0$9.6M
Lamy PatrickSenior VP, Commercial Strategy0$05$403,733$-403,733
Rolph TimothyChief Scientific Officer0$08$3.72M$-3.72M
White William RichardChief Financial Officer0$010$6.66M$-6.66M
Young JonathanChief Operating Officer0$017$7.35M$-7.35M
Yale CatrionaChief Development Officer0$020$9.39M$-9.39M
Cheng AndrewPresident and CEO0$012$12.14M$-12.14M

About Akero Therapeutics, Inc.

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH â€¦

Insider Activity of Akero Therapeutics, Inc.

Over the last 12 months, insiders at Akero Therapeutics, Inc. have bought $9.6M and sold $39.67M worth of Akero Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Akero Therapeutics, Inc. have bought $25.57M and sold $36.63M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Graham G. Walmsley (director) — $9.6M.

The last purchase of 200,000 shares for transaction amount of $9.6M was made by Graham G. Walmsley (director) on 2025‑01‑30.

List of Insider Buy and Sell Transactions, Akero Therapeutics, Inc.

2025-03-12SaleCheng AndrewPresident and CEO
1,738
0.0021%
$44.88$78,001-2.93%
2025-03-12SaleYoung JonathanChief Operating Officer
607
0.0007%
$44.88$27,242-2.93%
2025-03-12SaleRolph TimothyChief Scientific Officer
516
0.0006%
$44.88$23,158-2.93%
2025-03-12SaleYale CatrionaChief Development Officer
614
0.0008%
$44.88$27,556-2.93%
2025-03-12SaleWhite William RichardChief Financial Officer
676
0.0008%
$44.88$30,339-2.93%
2025-03-10SaleCheng AndrewPresident and CEO
30,000
0.0378%
$41.77$1.25M+6.78%
2025-03-05SaleRolph TimothyChief Scientific Officer
12,500
0.0154%
$44.53$556,590-2.95%
2025-03-04SaleYoung JonathanChief Operating Officer
50,000
0.0666%
$44.86$2.24M-1.22%
2025-03-03SaleLamy PatrickSenior VP, Commercial Strategy
1,000
0.0014%
$48.09$48,090-3.05%
2025-02-18SaleYale CatrionaChief Development Officer
10,000
0.0131%
$49.87$498,660-9.00%
2025-02-10SaleCheng AndrewPresident and CEO
30,000
0.0388%
$52.73$1.58M-8.03%
2025-02-05SaleRolph TimothyChief Scientific Officer
18,750
0.025%
$56.51$1.06M-15.60%
2025-02-03SaleYoung JonathanChief Operating Officer
10,000
0.0132%
$53.81$538,061-8.56%
2025-01-30PurchaseGraham G. Walmsleydirector
200,000
0.2547%
$48.00$9.6M-10.93%
2025-01-27SaleCheng AndrewPresident and CEO
30,000
0.0459%
$54.90$1.65M-4.28%
2025-01-27SaleRolph TimothyChief Scientific Officer
31,250
0.0486%
$55.77$1.74M-4.28%
2025-01-27SaleYale CatrionaChief Development Officer
102,664
0.1604%
$55.99$5.75M-4.28%
2025-01-27SaleLamy PatrickSenior VP, Commercial Strategy
5,000
0.008%
$57.03$285,150-4.28%
2025-01-02SaleYoung JonathanChief Operating Officer
10,000
0.0144%
$28.03$280,330+66.17%
2024-12-17SaleRolph TimothyChief Scientific Officer
3,800
0.0055%
$31.10$118,172+44.85%
Total: 249
*Gray background shows transactions not older than one year

Insider Historical Profitability

16.65%
Graham G. Walmsleydirector
1000000
1.256%
$44.15M100+42.32%
Apple Tree Partners IV, L.P.10 percent owner
5830203
7.3225%
$257.4M20<0.0001%
Versant Venture Capital VI, L.P.10 percent owner
3092698
3.8843%
$136.54M122+13.18%
venBio Global Strategic Fund II L.P.10 percent owner
3033552
3.81%
$133.93M125+13.18%
Atlas Venture Fund XI, L.P.10 percent owner
505099
0.6344%
$22.3M10+13.18%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$52,263,649
70
1.18%
$4.36B
$140,165,669
33
85.24%
$3.32B
$103,944,213
17
5.95%
$3.22B
$128,181,928
16
18.84%
$3.25B
$174,105,409
15
10.88%
$3.1B

AKRO Institutional Investors: Active Positions

Increased Positions105+60.34%9M+12.15%
Decreased Positions69-39.66%7M-9.03%
New Positions38New3MNew
Sold Out Positions20Sold Out368,386Sold Out
Total Postitions210+20.69%75M+3.13%

AKRO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Wellington Management Group Llp$362,356.009.84%7.38M-519,671-6.58%2024-12-31
Rtw Investments, Lp$336,955.009.15%6.86M+940,388+15.89%2024-12-31
Janus Henderson Group Plc$296,402.008.05%6.03M-1M-14.74%2024-12-31
Blackrock, Inc.$290,996.007.9%5.92M+176,393+3.07%2024-12-31
General Atlantic, L.P.$257,094.006.98%5.23M00%2024-12-31
Price T Rowe Associates Inc /Md/$212,295.005.76%4.32M+513,613+13.49%2024-12-31
Vanguard Group Inc$181,961.004.94%3.7M+27,830+0.76%2024-12-31
State Street Corp$114,742.003.12%2.34M-167,002-6.67%2024-12-31
Alliancebernstein L.P.$90,345.002.45%1.84M-177,807-8.81%2024-12-31
Alkeon Capital Management Llc$86,513.002.35%1.76M-2M-47.03%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.